Atle Fund Management AB Reduces Position in Cencora, Inc. $COR

Atle Fund Management AB decreased its position in shares of Cencora, Inc. (NYSE:COR) by 9.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,608 shares of the company’s stock after selling 2,858 shares during the period. Cencora accounts for 3.5% of Atle Fund Management AB’s investment portfolio, making the stock its 8th biggest holding. Atle Fund Management AB’s holdings in Cencora were worth $8,941,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in COR. Vanguard Group Inc. boosted its stake in Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after purchasing an additional 1,125,661 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock worth $1,429,772,000 after buying an additional 284,229 shares during the last quarter. Norges Bank bought a new stake in shares of Cencora in the second quarter valued at approximately $695,215,000. Viking Global Investors LP boosted its position in shares of Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the period. Finally, Amundi grew its stake in shares of Cencora by 17.0% in the second quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after acquiring an additional 249,742 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 20,316 shares of company stock valued at $7,151,265 over the last ninety days. 0.38% of the stock is owned by insiders.

Cencora Trading Up 2.0%

Shares of COR stock opened at $359.14 on Friday. Cencora, Inc. has a 12-month low of $237.71 and a 12-month high of $377.54. The firm has a 50-day moving average price of $347.62 and a 200 day moving average price of $324.08. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The company has a market capitalization of $69.67 billion, a P/E ratio of 45.17, a P/E/G ratio of 1.68 and a beta of 0.66.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period in the prior year, the company earned $3.34 EPS. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is presently 30.19%.

Wall Street Analyst Weigh In

COR has been the subject of several research analyst reports. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Wells Fargo & Company increased their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Robert W. Baird set a $415.00 target price on Cencora in a research report on Tuesday, January 13th. Finally, UBS Group upped their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.